Loading...
•
Dec 31, 2023
Tscan Therapeutics Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year 2023 and provided a business update.
Key Takeaways
TScan Therapeutics reported a revenue of $7.2 million for Q4 2023, compared to $3.1 million for Q4 2022. The net loss for the quarter was $19.6 million, compared to $18.7 million for the same period in 2022. As of December 31, 2023, the company's cash, cash equivalents, and marketable securities totaled $192.0 million.
Presented updated data from Phase 1 study of TSC-100 and TSC-101 for heme malignancies, showing 100% relapse-free patients in treatment arms.
Announced FDA clearance of two additional INDs for Solid Tumor Program: TSC-201-B0702 and TSC-204-A0101.
Solid tumor clinical trial actively enrolling, with initial data expected in 2024.
Expanded leadership team with key appointments and promotions.
Tscan Therapeutics
Tscan Therapeutics
Tscan Therapeutics Revenue by Segment
Revenue by Segment
Collab & License Revenue
CapyFin.com Forward Guidance
TScan Therapeutics anticipates several milestones for its Heme Malignancies and Solid Tumor Programs.
Positive Outlook
- Plans to open expansion cohorts at the recommended Phase 2 dose level to further characterize safety and evaluate translational and efficacy endpoints in the third quarter of 2024.
- Plans to complete Phase 1 enrollment and report one-year clinical and translational data on initial patients in 2024.
- Expects to initiate registration trial and report two-year relapse data in 2025.
- Initiated Phase 1 solid tumor clinical study and expects to dose the first patient in the first quarter of 2024.
- Expects to share initial data on patients from both singleplex and multiplex cohorts in 2024.